Tag: Alyftrek

According to market analysis following its late 2024 approval, Alyftrek carries an annual list price of approximately $370,000, representing a premium of about 7% over the established CF treatment, Trikafta. Understanding **how much does Alyftrek cost compared to Trikafta?** is critical for patients, providers, and healthcare systems navigating treatment options for cystic fibrosis (CF), as the comparison involves more than just the sticker price.

Breakthroughs in targeted therapy have transformed the treatment landscape for cystic fibrosis, with approximately 90% of eligible patients now benefiting from highly effective modulators. Today, the answer to what is the drug of choice for cystic fibrosis depends on a patient's specific genetic mutation, shifting the focus from symptom management to correcting the underlying cause.

The life expectancy for people with cystic fibrosis has dramatically improved over the past few decades, largely thanks to breakthrough medications called CFTR modulators. In late 2024, the U.S. Food and Drug Administration approved a powerful new triple-combination therapy called Alyftrek, building on the success of its predecessors and providing an important answer to the question: **What is the new drug for cystic fibrosis?**.

Over 90% of people with cystic fibrosis may be eligible for a new treatment called Alyftrek, which was approved by the FDA in December 2024 [1.4.2]. When considering this medication, a primary question is: how much does Alyftrek cost? The annual list price is approximately $370,269 [1.3.4, 1.3.6].

In a major advancement for cystic fibrosis (CF) care, the FDA approved Alyftrek in late 2024, and it became widely available in 2025, offering a significant upgrade for eligible patients. The question on many minds is, **what is the new CF drug 2025?** This once-daily triple-combination therapy simplifies treatment and continues the trend of targeted therapies that address the underlying cause of the disease.